A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Metastatic Breast Cancer

Trial Profile

A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Nivolumab (Primary) ; Paclitaxel (Primary) ; Carboplatin; Gemcitabine
  • Indications Advanced breast cancer; Non-small cell lung cancer; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb; Celgene Corporation
  • Most Recent Events

    • 06 Jun 2017 Interim results (n = 20) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Apr 2017 Planned End Date changed from 1 Dec 2017 to 26 Oct 2018.
    • 21 Jan 2017 Interim results from the pancreatic cancer cohort (n=17; data cut off: June 28, 2016) presented at the 2017 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top